kras-inhibitors
(3)
Quanta Therapeutics
Quanta Therapeutics is a clinical-stage biopharmaceutical company in South San Francisco building allosteric small-molecule inhibitors for RAS-driven cancers. Using a proprietary Second Harmonic Generation (SHG) optical platform that detects subtle changes in protein conformation, Quanta designs oral drugs aimed at KRAS mutations long considered undruggable - including G12D and G12V - that together drive a large share of pancreatic, colorectal, lung and endometrial cancers. Its lead candidate QTX3034 is in Phase 1 trials, with QTX3544 and a pan-KRAS program close behind.
Perry Nisen
Perry Nisen is a physician-scientist and CEO of Quanta Therapeutics, a South San Francisco biotech building next-generation oral KRAS inhibitors for RAS-driven cancers. A former pediatric oncologist turned pharma executive, he ran the GSK oncology portfolio later acquired by Novartis for over $16 billion, led the Sanford Burnham Prebys research institute, and serves on Teva's board. He now chases the 'undruggable' mutations that drive a quarter of all human cancers.
Jung Choi
Jung Choi is the President and CEO of Alterome Therapeutics, a clinical-stage precision oncology company pioneering mutation-specific cancer drugs. With over 20 years in biopharmaceutical leadership - spanning Gilead Sciences, InterMune, Chimerix, and Global Blood Therapeutics where he led a $5.4B Pfizer acquisition - Choi brought deal-making, strategy, and operational depth to Alterome when he was appointed CEO in April 2025. Under his leadership, Alterome has advanced two first-in-class inhibitors into Phase 1/1b trials targeting KRAS and AKT1 E17K oncogenic drivers, backed by $231M in total funding including a $132M Series B.